We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
-7.99%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$18.4B
AUM Growth
-$2.28B
Cap. Flow
-$623M
Cap. Flow %
-3.38%
Top 10 Hldgs %
32.43%
Holding
345
New
22
Increased
43
Reduced
37
Closed
30

Sector Composition

Rank Sector Weight
1 Healthcare 30.97%
2 Technology 17.59%
3 Financials 14.68%
4 Industrials 9.18%
5 Communication Services 8.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
IPVF
176
DELISTED
InterPrivate III Financial Partners Inc.
IPVF
$3.92M 0.02%
400,000
FRSG
177
DELISTED
First Reserve Sustainable Growth Corp. Class A Common Stock
FRSG
$3.91M 0.02%
400,000
CITE
178
DELISTED
Cartica Acquisition Corp Class A Ordinary Shares
CITE
$3.51M 0.02%
350,000
VMGA
179
DELISTED
VMG Consumer Acquisition Corp. Class A Common Stock
VMGA
$3.49M 0.02%
350,000
UTAA
180
DELISTED
UTA Acquisition Corporation Class A Ordinary Shares
UTAA
$3.41M 0.02%
344,100
-5,900
-2% -$59K
SPCM
181
DELISTED
Sound Point Acquisition Corp I, Ltd Class A Ordinary Share
SPCM
$3.02M 0.02%
+300,000
New +$3M
LGV
182
DELISTED
Longview Acquisition Corp. II
LGV
$2.98M 0.02%
304,698
BCSA
183
DELISTED
Blockchain Coinvestors Acquisition Corp. I Class A Ordinary Shares
BCSA
$2.98M 0.02%
300,000
LGAC
184
DELISTED
Lazard Growth Acquisition Corp. I Ordinary Shares
LGAC
$2.93M 0.02%
300,000
RCEL icon
185
Avita Medical
RCEL
$311M
$2.75M 0.01%
580,000
-220,000
-28% -$1.36M
LBPH
186
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$2.5M 0.01%
810,500
SCLE
187
DELISTED
Broadscale Acquisition Corp. Class A common stock
SCLE
$2.46M 0.01%
250,000
LOKM
188
DELISTED
Live Oak Mobility Acquisition Corp.
LOKM
$2.45M 0.01%
250,000
HIII
189
DELISTED
Hudson Executive Investment Corp. III Class A Common Stock
HIII
$2.45M 0.01%
250,000
CLVR
190
DELISTED
Clever Leaves Holdings Inc. Common Shares
CLVR
$2.41M 0.01%
82,230
+1,016
+1% +$40.6K
THRX
191
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$2.27M 0.01%
409,717
-114,262
-22% -$944K
LMACA
192
DELISTED
Liberty Media Acquisition Corporation Series A Common Stock
LMACA
$2.07M 0.01%
210,000
+94,342
+82% +$932K
ANAC
193
DELISTED
Arctos NorthStar Acquisition Corp.
ANAC
$1.96M 0.01%
200,000
BTTX
194
DELISTED
Better Therapeutics, Inc. Common Stock
BTTX
$1.56M 0.01%
1,000,000
-147,400
-13% -$247K
AEON icon
195
AEON Biopharma
AEON
$9.58M
$1.47M 0.01%
2,083
TNGX icon
196
Tango Therapeutics
TNGX
$4.03B
$1.36M 0.01%
300,000
IMA
197
ImageneBio Inc
IMA
$62.5M
$1.28M 0.01%
24,167
-41,839
-63% -$2.31M
TMAC
198
DELISTED
The Music Acquisition Corporation
TMAC
$1.23M 0.01%
125,000
LIAN
199
DELISTED
LianBio American Depositary Shares
LIAN
$1.08M 0.01%
+500,000
New +$1.7M
DAOO
200
DELISTED
Crypto 1 Acquisition Corp Class A Ordinary Shares
DAOO
$991K 0.01%
100,000

Similar funds

Thomas Steyer's Q2 2022 Portfolio in Review

As of Q2 2022, Thomas Steyer held 345 positions worth $18.4B, down 11% from $20.7B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Thomas Steyer withdrew a net $623M in Q2 2022, closing 30 positions and reducing 37 holdings. Its most notable exit was ZYNGA INC. CL A COMMON, an estimated $411M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 31% a quarter earlier, followed by Technology and Financials.

Against the trend, Thomas Steyer opened a new position in Twitter, Inc. worth $274M.

  • Thomas Steyer's largest Q2 2022 buy was Twitter, Inc.: 7,325,000 shares worth $274M.
  • Thomas Steyer added most to Clarivate in Q2 2022, an estimated $237M increase.
  • Thomas Steyer's biggest Q2 2022 reduction was AbbVie, cutting an estimated $97.7M.
  • Thomas Steyer fully exited ZYNGA INC. CL A COMMON in Q2 2022, selling an estimated $411M.
  • Thomas Steyer's ten largest holdings make up 32% of its $18.4B portfolio in Q2 2022.
  • Thomas Steyer opened 22 new positions and closed 30 in Q2 2022.
  • Thomas Steyer's portfolio value fell 11% quarter-over-quarter to $18.4B.

Based on Farallon Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.